Why Are Overseas Registration Timelines for IVD Products Extended?

Why Are Overseas Registration Timelines for IVD Products Extended?

The prolonged timeline for overseas registration of IVD products is primarily due to regulatory policy changes in target countries, misjudgment of product risk classification, technical documentation not meeting local requirements, insufficient clinical evidence, quality management systems not aligned with international standards, inadequate localization of labels and instructions for use (IFU), inappropriate selection of local agents or authorized representatives, and lack of a post-market surveillance plan. Enterprises often resubmit documentation by neglecting regulatory differences or fail to assess the applicability of existing NMPA, CE, or FDA files before reuse.

Key Summary

• Regulatory policy changes in target markets
• Risk classification errors leading to inappropriate registration paths
• Technical documentation not meeting local requirements
• Insufficient clinical evidence or lack of localization
• Quality management system non-conformance (e.g., ISO 13485, MDSAP)
• Inadequate localization of labels and IFU
• Inappropriate local agent or authorized representative
• Missing post-market maintenance plan

Applicable Scenarios and Core Issues

This article applies to enterprises planning to export IVD products to overseas markets, especially GHWP member countries, Southeast Asia, the Middle East, and Latin America. The core issue is why registration timelines exceed expectations. While 6 months to 2 years is typical, delays to over 3 years are common. The main contradiction lies in underestimating regulatory diversity and review uncertainty.

Registration Logic

Step 1: Determine if the product falls under the medical device regulatory scope in the target country. Some countries exclude calibrators, controls, or sample processing reagents; others include them strictly.
Step 2: Determine risk classification based on local rules (e.g., EU IVDR classification, ASEAN MDACS A/B/C/D). Different paths have vastly different timelines.
Step 3: Assess reusability of existing documentation. Enterprises with NMPA, CE IVDR, FDA 510(k)/PMA, ISO 13485, or MDSAP certificates may simplify submissions in some countries, but must supplement local epidemiological data, reference intervals, shipping validation, etc.
Step 4: Confirm requirements for technical files, performance validation, risk management, clinical evaluation/evidence, labels/IFU, local agent, authorized representative, and post-market surveillance. For example, Brazil ANVISA requires Portuguese labels and a local authorized representative.

Documentation and Evidence

Core documentation: Product technical specifications (performance, reference intervals, accuracy, precision, linear range), risk management report (ISO 14971), clinical evaluation or trial data, QMS certificate, label and IFU drafts, packaging validation, stability studies, software validation (if applicable).
Reusable evidence: ISO 13485 or MDSAP certificate as QMS basis; CE technical files for performance and risk management; FDA clinical data accepted in some countries (e.g., Health Canada). However, all evidence must be translated into the target language and adapted to local regulations. For instance, reference intervals based on Chinese populations must be re-established for Indonesian markets.
Non-reusable evidence: Labels and IFU must be fully localized (language, units, symbols, warnings). Shipping validation must be based on actual routes, e.g., high temperature/humidity tests for tropical climates.

Common Mistakes

• Misclassification: Classifying high-risk products as low-risk, leading to delayed supplemental clinical data requests.
• Direct reuse of NMPA or CE files without localization (e.g., missing local epidemiology, untranslated labels).
• Not appointing a qualified local agent in advance; poor agent qualifications or high turnover results in unresponsive correction requests.
• Ignoring post-market maintenance: Many countries require annual reports, change notifications, and adverse event reporting; lack of such processes can lead to certificate suspension or revocation.
• Unrealistic timeline planning: Not accounting for review queues, correction cycles, or factory inspection scheduling.
• Duplicate work for multi-country registrations: Not using modular documentation, causing inefficiency.

Enterprise Preparation Checklist

• Confirm product classification in target country and document the basis.
• Collate reusable technical files: NMPA certificate, CE technical files, FDA submissions, ISO 13485, MDSAP.
• Prepare localized labels and IFU (language, format, content).
• Identify or assess local agent/authorized representative qualifications.
• Verify if performance validation (reference intervals, accuracy, precision) needs local population data.
• Prepare clinical evaluation or trial data; assess if predicate device comparison is accepted.
• Establish post-market surveillance (PMS) and vigilance system documents.
• Create a multi-country registration timeline with buffers for corrections and factory inspections.
• Confirm if factory inspection is required (e.g., Brazil ANVISA, Saudi SFDA).
• Prepare registration application forms and local language versions.

AIMEILI’s Perspective

Enterprises often mistakenly believe that having a CE or FDA certificate allows quick entry into other countries. In reality, each country has its own technical file independence; for example, clinical performance studies under CE IVDR may not align with Southeast Asian requirements. We recommend performing a regulatory gap analysis early to identify reusable versus mandatory new content.
First, confirm product classification and registration path—this determines documentation needs and timeline. Core technical files like performance validation and risk management can form a generic module, but labels, IFU, clinical evidence, and QMS certificates must be adapted per country. Second, selecting a competent local agent is critical; the agent not only submits files but also handles corrections, change applications, and renewal management. Control of certificates must remain with the enterprise to avoid issues if the agency relationship ends. For multi-country registrations, adopt a “1+N” model: base technical file plus country-specific attachments to reduce rework and correction risks. Additionally, post-market maintenance capability is key to sustained registration—establish processes for periodic reports, change notifications, and adverse event reporting; otherwise, certificates may be revoked despite initial approval.

Frequently Asked Questions

Q1: IVD product classification varies significantly between countries. How can we quickly determine the target country’s classification?
Refer to the classification guidelines or registration rules published by the target country’s health authority. For example, the Thailand FDA classifies IVD reagents into A, B, C, D categories, consistent with ASEAN MDACS. You may also consult global classification databases (e.g., GMDN), but always confirm via official pre-classification request with the local agent or consultant to avoid misjudgment.

Q2: If we only have a CE IVDR certificate and no other market experience, what is the typical registration timeline?
Enterprises with CE IVDR certificates are usually 30–50% faster than those starting from scratch, but still need localized documentation. For Southeast Asian countries, the review cycle is typically 6–12 months; if reference interval data is required, allow an additional 3–6 months. We recommend collecting target population samples in advance for validation and documenting test reports to shorten correction cycles.

Q3: How can we reduce duplicate work for multi-country registrations?
Adopt a modular technical file structure: core modules for performance validation, risk management, clinical evaluation, etc., and adjust only the introduction, regulatory statements, label language, etc., for each country. Leverage mutual recognition systems, such as MDSAP certificates accepted directly in some countries, reducing QMS audits. Also, plan registration order strategically—start with countries with similar review requirements (e.g., ASEAN member states) to gain experience before expanding.

Note: This article is compiled from AIMEILI’s registration practice database, medical device international registration knowledge base, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country’s regulatory authority and the product documentation. This content is for general guidance and does not replace official requirements or legal advice.

Source: AIMEILI Regulatory Editorial Department
Expert Review: AIMEILI Medical Device International Registration Project Team
Date: 2026-07-29